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FOR MANY YEARS, RECOMMENDA-tions about the use of hormonereplacement therapy (HRT) inpostmenopausal women have
been based largely on observational stud-
ies, which suggest that HRT reduces the
risk of coronary heart disease.1"3 The
likely mechanisms are numerous4 and
include the beneficial effects of estro-
gens on lipids.5 But estrogens are also
known to be prothrombotic.6 In men
with prostate cancer or cardiovascular
disease7·8 and in women on oral contra-
ceptives,9 high doses or potent formu-
lations of estrogens are associated with
thrombotic complications, including
myocardial infarction (MI), stroke, and
venous thrombosis. In postmeno-
pausal women, HRT is also a risk fac-
tor for venous thrombosis.10"13
The results of the Heart and Estrogen/
progestin Replacement Study (HERS)
have renewed interest in the potential
adverse effects of HRT.12 ° In this ran-
domized clinical trial of secondary pre-
vention, combined HRT was no better
than placebo at preventing coronary
events in postmenopausal women (rela-
tive risk [RR], 0.99; 95% confidence m-
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Context Estrogens are known to be prothrombotic, and findings from the Heart and
Estrogen/progestin Replacement Study suggest that in women with clinically recog-
nized heart disease, hormone replacement therapy (HRT) may be associated with early
härm and late benefit in terms of coronary events.
Objective To assess whether, äs hypothesized, prothrombotic mutations modify the
association between HRT use and incidence of first myocardial infarction (MI).
Design and Setting Population-based, case-control study conducted in a Seattle-
based health maintenance organization.
Participants Cases were 232 postmenopausal women aged 30 to 79 years who had
their first nonfatal MI between 1995 and 1998. Controls were a stratified random sample
of 723 postmenopausal women without MI who were frequency-matched to cases
by age, calendar year, and hypertension Status.
Main Outcome Measure Risk of first nonfatal MI based on current use of HRT
and the presence or absence of coagulation factor V Leiden and prothrombin 20210
G->A variants among cases and controls, stratified by hypertension.
Results One hundred eight MI cases and 387 controls had hypertension and 124 MI
cases and 336 controls did not. Among hypertensive women, the prothrombin variant
was a risk factor for MI (odds ratio [OR], 4.32; 95% confidence interval [Cl], 1.52-
12.1) and, in this stratum, there was also a significant interaction between use of HRT
and presence of the prothrombin variant on risk of MI. Compared with nonusers of HRT
with wild-type genotype, women who were current users and who had the prothrom-
bin variant (n =8) had a nearly 11-fold increasein risk of a nonfatal MI (OR, 10.9; 95%
Cl, 2.15-55.2). The interaction with the prothrombin variant was more pronounced in
analyses assuming 100% compliance than in those assuming 80% compliance with HRT.
The interaction was absent among nonhypertensive women and was less pronounced
if hypertensive and nonhypertensive women were combined into 1 group. No interac-
tion was found for factor V Leiden in either hypertensive or nonhypertensive women.
Among hypertensive women, the estimates were affected only in trivial ways by ad-
justment, and the interaction with the prothrombin variant was specific to HRT.
Conclusions Our results suggest that among postmenopausal hypertensive women,
the association between HRT use and MI risk differed between those with and with-
out the prothrombin 20210 G->A variant. If these findings are confirmed in other stud-
ies, screening for the prothrombin variant may permit a better assessment of the risks
and benefits associated with HRT in postmenopausal women.
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terval [Cl], 0.81-1.22). In post-hoc
analyses, treatmentwas associated with
early härm during the first year of fol-
low-up (RR, 1.52; 95% Cl, 1.01-2.29)
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and a late benefit during follow-up years
4 and5 (RR, 0.75; 95% CI, 0.50-1.13).
One broad hypothesis offered to ex-
plain this pattern of risks was the pos-
sibility of "an immediate prothrom-
botic, proarrhythrnic, or proischemic
effect of treatment that is gradually out-
weighed by a beneficial effect on the un-
derlying progression of atherosclero-
sis."12'13 According to this Interpretation,
a subgroup—perhaps defined by a clini-
cal characteristic, an environmental
exposure, or a genetic trait—is suscep-
tible to an early adverse effect of estro-
gens while the rest of the population
benefits from estrogen therapy. When
a therapy produces effects that differ by
more than chance Variation in 2 sub-
groups, an interaction is present.
Genetic variants are excellent can-
didates for such interactions. Vanden-
broucke et al14 have described an in-
teraction between oral contraceptives
and factor V Leiden on the risk of deep
venous thrombosis. While factor V
Leiden and the prothrombin 20210
G—»A variant are clearly associated with
the risk of venous thrombosis,15 re-
ports of an association between these
prothrombotic variants and coronary
heart disease have been inconsistent,
some finding an increased risk,16"19
while others do not.20'24 Whether HRT
places women with either of these 2
prothrombotic variants at an espe-
cially high risk of MI remains un-
known. Before the results of HERS were
published or known to us, we initi-
ated a po.pulation-based, case-control




The setting for this project was Group
Health Cooperative (GHC), a Seattle,
Wash-based health maintenance orga-
nization with an enrollment of more
than 400000. The methods have been
described previously25·26 and will be
summarized only briefly here. The
study was reviewed and approved by
human subjects committees at both
3HC and the University of Washing-
.on, Seattle. All subjects gave written
informed consent before initiating the
study. During the period of this study,




Cases were female GHC enrollees who
survived an incident MI between Janu-
ary 1995 and December 1998. Poten-
tial cases were identified from 2 sources:
(1) the computerized discharge abstracts
for the 2 GHC hospitals; and (2) the
GHC claims databases, which include
bills for all Services provided by non-
GHC physicians and health care facili-
ties. We have used and evaluated simi-
lar methods in previous case-control
studies.25"28 Due to different funding
sources, cases were stratified on hyper-
tension Status äs assessed by the com-
puterized pharmacy database. Con-
trols were a stratified random sample of
postmenopausal female GHC enrollees
sampled from the GHC computerized
enrollment files on the basis of person-
time.29 Controls were frequency matched
to the cases by age (within decade), cal-
endar year, and hypertension Status at
a ratio of approximately 3 to 1. Con-
trols met the same eligibility criteria äs
the cases, but they had not had an MI.
Grants from the National Institutes of
Health and the American Heart Asso-
ciation funded primary data collection
on cases with and without hyperten-
sion, respectively.
Index Dates and Eligibility
All women had an index date. For the
cases, the index date was the date of ad-
mission for the first acute MI; and for
the controls, the index date was a com-
puter-generated random date within the
same calendar year for which they had
been chosen äs controls. For all women,
we only collected risk factor data avail-
able before the index date. This ap-
proach ensured that cases and con-
trols met the same eligibility criteria. All
women were aged 30 to 79 years at their
index dates. For all subjects, we ex-
cluded women who were members of
GHC for less than l year or who did not
have at least 4 physician visits prior to
their index dates; women who had had
a prior MI; and women who were not
postmenopausal. Additionally, we
excluded cases whose index event was
a complication of a procedure or a
surgery.
Data Collection and
Definition of HRT Use
Data collection included a review of the
GHC outpatient medical record, a tele-
phone interview, and a venous blood
sample from women who consented to
participate. Based on the medical rec-
ord, research assistants determined eli-
gibility and collected Information about
the following traditional risk factors for
coronary heart disease: blood pressure
and pulse; height and weight; choles-
terol level, Smoking Status, family his-
tory, hysterectomy Status, marital Sta-
tus, and use of health Services; medical
conditions such äs angina, hyperten-
sion, diabetes, congestive heart failure,
stroke, and peripheral vascular dis-
ease. Cardiovascular disease was de-
fined äs a history of angina, stroke,
claudication, or vascular procedures, in-
cluding coronary bypass, angioplasty, ca-
rotid endarterectomy, or peripheral vas-
cular bypass. Research assistants were
not blinded to case-control Status.
The GHC computerized pharmacy da-
tabase was used to assess current HRT
use at the index date. Since 1976, the
GHC pharmacy database has included
a record for all prescriptions dispensed
to GHC enrollees. Each pharmacy re-
cord includes a patient identifier, the
drug type and dose, the date, the quan-
tity dispensed, and dosing instruc-
tions. For determining current use, we
searched the pharmacy data for the hor-
mone prescription immediately preced-
ing the reference date. When a woman
(who was at least 80% compliant) re-
ceived enough puls to last until her in-
dex date, she was counted äs a current
user; otherwise, she was counted äs a
nonuser. For 80% compliance, a woman
who received 100 puls with instruc-
tions to take l pill per day was counted
äs a current user for 125 days (from 1007
0.8) after the prescription dispensing
date. Current progestin use was de-
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fined in the same way. In preplanned
sensitivity analyses, we reanalyzed data
that defined current HRT use assum-
ing 100% rather than 80% compliance.
For 100% compliance, a woman who re-
ceived 100 pills with instructions to take
l pill per day was counted äs a current
user for 100 days after the prescription
dispensing date. Only users of oral es-




A blood specimen was drawn from the
antecubital vein into tubes containing
edetic acid and kept at 4°C until the
blood was initially processed. Buffy coats
were prepared, washed in saline, and
stored at -70°C. Specimens were shipped
on dry ice to the laboratory in Leiden,
the Netherlands. The DNA was ex-
tracted from the white blood cells us-
ing Standard salting-out procedures.30
The Status of the prothrombin variant
(20210 G—>A) was assessed by the pres-
ence of a Hindill restriction site in the
polymerase chain reaction fragment.31
The presence of factor V Leiden (1691
G—>A) was assessed by the loss of an
Mnll restriction site äs originally de-
scribed by Bertina et al.32 Laboratory per-
sonnel were blinded to case-control Sta-
tus and to HRT Status.
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*Values are expressed äs percentages unless otherwise indicated.
tValues are expressed äs means.
ihieterozygous or homozygous for the variant allele.
§P<.05 for the companson between cases and controls separately for those with and without hypertension.
Statistical Analysis
In comparing case and control charac-
teristics, we used the i test for continu-
ous variables, the χ2 test for categorical
variables, and the Fisher exact test. Be-
cause of the Stratified sampling, the
analysis was Stratified on hypertension
Status. Odds ratios (ORs) and CIs were
estimated in the Standard way,33·34 and
logistic regression was used for multi-
variable analysis. The ORs estimating the
association between HRT and MI were
also calculated separately in the 2 strata
defined by genotype: (1) women with a
prothrombotic variant (susceptible wom-
en); and (2) women with the wild-type
(normal) genotype (nonsusceptible
women). All Statistical tests were 2-tailed.
For the primary analysis, we classi-
fied women äs current or not current us-
ers of HRT at their index dates by the
80% compliance method. The current
users were compared with the noncur-
rent users. Women with a prothrom-
botic variant were compared with
women with the wild-type genotype.
Formal tests for interaction were car-
ried out with both case-control and case-
only methods,35·36 which are more effi-
cient and powerful than case-control
methods.37 Both methods estimate the
synergy index (SI), which is a ratio of
the OR in the susceptible women to the
OR in the nonsusceptible women. An SI
of l means that the ORs in the 2 sub-
groups were the same and that there was
no interaction on the multiplicative
scale; a SI of greater than l means that
the joint effect of gene and the drug were
supramultiplicative compared with their
expected effect, which is the product of
their individual effects.
RESULTS
Of the 955 women, 108 cases and 387
controls had hypertension, and 124 cases
and 336 controls were in the stratum
without hypertension. The control-to-
case matching ratio was higher in the hy-
pertensive (3.6:1) than in the nonhy-
pertensive (2.7:1) women. Genotype
assays were available for 950 women for
factor V Leiden and for 953 women for
the prothrombin variant. Factor V
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Leiden was present m 23 hypertensive
and 25 nonhypertensive women, and no
homozygotes were present The pro-
thrombin vanant was present m 15 hy-
pertensive and 15 nonhypertensive
women One additional nonhyperten-
sive control was homozygous for the
vanant prothrombm allele
Within each stratum, frequency
matching produced a control group
with a mean age close to that of the
cases (TABLE 1) In both the hyperten-
sive and the nonhypertensive strata,
diabetes, smoking, physical activity,
cholesterol, high-density hpoprotem
cholesterol, glucose, family history, and
a history of angina differed between
cases and controls in the expected man-
ner Among nonhypertensive women,
weight and systolic and diastolic blood
pressure also differed sigmficantly be-
tween cases and controls Among the
hypertensive women, weight, systolic
blood pressure, and mean time en-
rolled in GHC were similar m the cases
and controls
TABLE 2 summanzes the main ef-
fects of HRT, factor V Leiden, and the
prothrombm vanant on MI nsk Among
hypertensive women, current HRT use
and factor V Leiden were only weakly
associated with MI nsk On the other
band, the prothrombm vanant was as-
sociated with an mcreased nsk of MI in
hypertensive women (OR, 4 32,95% CI,
1 52-12 1), after adjustment for covar-
lates, the OR mcreased to 7 02 (95% CI,
2 27-21 8) Among nonhypertensive
women, there was little association of
HRT or either prothrombotic vanant
with case-control Status, before or after
adjustment for covanates
TABLE 3 summanzes the stratified
analyses for the prothrombm vanant
Table 2. Association of Hormone Replacement Therapy, Factor V Leiden, and the





















































1 02 (0 66 1 59)
1 00
0 67 (0 31 1 48)
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0 66 (0 24-1 81)
1 00




1 28 (0 78 2 09)
1 00
061 (023 1 61)
1 00
7 02 (2 27 21 8)
1 00




0 79 (0 23 2 70)
*Adjusted for age calendar year smoking
diabetes
cardiovascular disease systolic blood pressure total cholesterol and





























































0 89 (0 56 1 42)
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0 89 (0 56 1 42)

























*OR indicates odds ratio Sl Synergy Index
tCalculated by Fisher exact test
tCalculated by the likelihood ratio method
and NA not applicable
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Table 5. Effect of Adjustment on the Association of Hormone Use and Prothrombin Variant









































*Values are expressed äs odds ratio (95% Confidence interval).
Hypertensive women who had the wild-
type genotype for prothrombin and who
were not current users of HRT served
äs the reference group. Among women
with the wild-type genotype, HRT use
was associated with a small reduction
in the risk of nonfatal Ml (OR, 0.89;
95% CI, 0.56-1.42). Compared with the
reference group, women who had the
prothrombin variant and who were not
current users of HRT had only a small
increase in the OR to 1.45 (95% CI,
0.28-7.66). In the absence of an inter-
action (on a multiplicative scale), the
expected joint effects of the prothrom-
bin variant and current HRT use would
be 1.29. Compared with the reference
group, the 8 women who had the
prothrombin variant and who were
current users of HRT had an almost
11-fold increase in the risk of Ml (OR,
10.9; 95% CI, 2.15-55.2; P = .002).
The analyses stratified on suscep-
tibility also appear in Table 3. Among
the 478 nonsusceptible, hypertensive
women (with prothrombin wild type),
HRT use was associated with a slight
decrease in the risk of MI (OR, 0.89).
Among the 15 susceptible, hyperten-
sive women (with prothrombin vari-
ant), HRT use was associated with an
increased risk of MI (OR, 7.50; 95% CI,
0.76-74.2; P= .10). The case-control es-
timate of the Sl was 8.38 (95% CI, 0.81-
86.8; P=.06). The case-only estimate of
the Sl was similarat 5.57 (95% CI, 1.07-
29.1; P = .03) and indicated a signifi-
cant interaction between HRT and the
prothrombin variant on the risk of non-
fatal MI among hypertensive women.
When the analysis was restricted to
whites only (data not shown), the case-
control Sl was 8.62 (95% CI, 0.83-
89.4); the corresponding case-only Sl
was 5.38 (95% CI, 1.03-28.15). When
we assumed 100% rather than 80%
compliance, the evidence of an inter-
action became more pronounced with
a case-control Sl of 23.9 (95% CI, 1.61-
354; P =.008).
Among women without hyperten-
sion, no cases had the prothrombin
variant and used HRT, There was no
evidence of an interaction. Combin-
ing estimates from these 2 strata, de-
fined by hypertension Status, did not ap-
pear to be appropriate. If hypertensive
and nonhypertensive women were
combined into a single group, the in-
teraction would have been less pro-
nounced (Sl, 2.0; 95% CI, 0.45-8.95).
TABLE 4 summarizes the data for fac-
tor V Leiden in the same formal used
for the prothrombin variant. Again,
women who were not current users by
the 80% compliance method and who
did not have factor V Leiden served äs
the reference group. Individually or
jointly, there was little association be-
tween HRT use or factor V Leiden and
MI risk. None of the CIs for these as-
sociations excluded the null hypoth-
esis. The SIs estimated by both the case-
control and the case-only methods were
small and did not differ from the null
hypothesis of no interaction.
The small number of hypertensive
women with the prothrombin variant
(n= 15) limited the ability to adjust for
Potential confounding factors. TABLE 5
summarizes the effect of adjustment for
a number of covariates one at a time.
The unadjusted OR estimates are the
same äs in Table 3: 0.89 for HRT use,
l .45 for the prothrombin variant, and
10.9 for the combination of HRT use
and the prothrombin variant. Adjust-
ments for age, calendar year, race,
smoking, diabetes, cardiovascular dis-
910 JAMA, February 21, 2001—Vol 285, No 7
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ease, systolic blood pressure, or cho-
lesterol each had httle effect on the
pomt estimates The lowest adjusted OR
for the combination of HRT use and the
prothrombm vanant was 10 4, and the
lower hmit of the 95% CIs never went
below l 97
TABLE 6 summanzes the fmdings of
a series of analyses that attempted to
identify other potential mteractions
with the prothrombin vanant on the
nsk of MI, pnmanly among women
with hypertension The SIs for HRT
use at 80% and 100% compliance were
8 38 (95% CI, 0 81-86 8) and 23 9
(95% CI, l 61-354), respectively No
other characteristic was associated
with such an elevated SI For most of
the characteristics, the ORs for MI nsk
were similar among those with and
without the prothrombin vanant For
the association between cardiovascular
disease (such äs angma) and MI nsk,
the OR was higher among those with
the prothrombm vanant (OR, 6 00,
95% CI, 0 48-75 4) than among those
without the prothrombin vanant (OR,
2 92, 95% CI, l 79-4 78) The SI for
cardiovascular disease was 2 05 (95%
CI, 0 16-27 0) Zero entnes precluded
the abüity to examine an interaction
for smokmg and for diabetes m the
hypertensive women, but there was no
evidence of an interaction in the popu-
lation äs a whole
Among the controls, 85 7% of HRT
users were takmg estenfied estrogens,
and most of the others were takmg con-
jugated estrogens Estrogen patches were
rarely used at GHC (2 cases and 2
controls) Among the 8 hypertensive
women currently takmg HRT and hav-
mg the prothrombin vanant, the 6 cases
had a slightly smaller mean number of
hfetime prescnpüons for estrogens than
the 2 controls (31 vs 39, P= 71) One
of the 6 cases had started HRT 7 months
pnor to her MI while the other 5 had
been regulär users for a least l year be-
fore their MI event Among the 6 hy-
pertensive cases who had the prothrom-
bm vanant and who were cunent users
of HRT, all 6 were usmg estenfied es-
trogens, 5 of the 6 were takmg estro-
gen alone rather than m combination

















0 89 (0 56 1 42) 7 50 (0 76-74 2)
075(047-121) 180(127-256)
2 92 (1 79-4 78) 6 00 (0 48-75 4)
219(139344) 150(017-132)
051(032081) 050(004710)
0 93 (0 60-1 45) 0 80 (0 10-6 35)
2 23 (1 41 -3 53) 3 60 (0 28-46 4)
All Subjects
4 1 4 (2 70-6 36) 510 (0 47-55 9)




23 9 (1 61 354)
205(016270)
0 69 (0 07-6 33)
098(007-145)
086(010-716)
1 62(012 21 7)
1 23(011 140)
084(007 108)
*Values are expressed äs odds ratio (95% confidence mterval) unless otherwlse indicated
tValues are expressed äs synergy mdex (95% confidenoe mterval)
with a progestm, and 5 were takmg 0 625
mg/d and l was takmg 0 3 mg/d The an-
ühypertensive medicattons used by diese
6 women were similar to the agents typi-
cally used at GHC, and 3 of the 6 were
takmg atenolol
COMMENT
In this populaüon-based, case-control
study, the prothrombin 20210 G-*A
vanant was a risk factor for MI among
hypertensive women There was also a
sigmficant interaction between the use
of HRT and the prothrombin vanant on
the nsk of MI among women with hy-
pertension Compared with the refer-
ence group, the 8 women who were cur-
rent HRT users and who had the
prothrombin vanant had a nearly 11-
fold mcrease in the nsk of a nonfatal MI
(OR, 10 9,95% CI, 2 15-55 2) The 95%
CI of the SI äs assessed by the more pow-
erful case-only method, a formal test for
a multiplicative interaction, excluded the
null hypothesis (Table 3) The interac-
tion was more pronounced for the 100%
compliance method than for the 80%
compliance method of defmmg cur-
rent HRT use (Table 3) No such inter-
action was found for nonhypertensive
women (Table 3) or for factor V Leiden
m either the hypertensive or the non-
hypertensive women (Table 4) Among
the hypertensive women, the estimates
were affected only in trivial ways by ad-
justment for potential confounding fac-
tors (Table 5) The interaction with the
prothrombm vanant was speafic to HRT
use and not to other characteristics
(Table 6)
The prothrombin vanant has been as-
sociated with an mcreased mcidence of
venous thrombosis and with elevated
levels of prothrombin in plasma 31 In
other observational studies, the pro-
thrombin vanant has been associated
with the mcidence of MI in some stud-
ies17 19 but not m others 2022 24 While
previous studies have identified poten-
tial mteractions of oral contraceptive
use with factor V Leiden14 and of HRT
use with activated protein C resis-
tance38 on the mcidence of venous
thrombosis, there are no previous epi-
demiologic reports of an interaction be-
tween HRT use and prothromboüc van-
antson thenskofMI The only cross-
secüonal analysis, conducted m women
with hyperhpidemia, assessed HRT use
at the trnie of the clinic visit rather than
at the Urne of the cardiovascular event39
This study had a number of hmita-
tions Due to the low prevalence of the
prothrombin vanant, it was not pos-
sible to adjust simultaneously for mul-
tiple potential confounding factors in
a smgle modelw While the healthy user
effect is often invoked to explain the as-
sociation between HRT use and a de-
creased nsk of cardiovascular events,41 n
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such biases are less likely to be impor-
tant in studies of genetic variants äs risk
factors. In addition to the possibility of
confounding, potential alternative ex-
planations for the findings of genetic as-
sociation studies include linkage dis-
equilibrium and population admixture.
The results were also based on a small
number of women with the genetic vari-
ant, so there remained considerable sta-
tistical uncertainty around the risk es-
timates reported in this study.
For both the prothrombin variant
and factor V Leiden, we had expected,
but did not find, similar interactions
with HRT use. The cases in this study
all represent survivors of an MI, and it
is possible that the interaction may af-
fect mortality rather than disease inci-
dence. If, for instance, the joint effects
of factor V Leiden and HRT use are as-
sociated with a high case-fatality rate,
a case-control study of nonfatal MI
would fail to detect an interaction. On
the other band, survival bias is un-
likely to induce the interaction seen
with the prothrombin variant and HRT
use in this study.
For the prothrombin variant, the find-
ings of an interaction among those with
hypertension were not confirmed by the
findings among those without hyper-
tension. Several explanations, includ-
ing chance, are possible. Three of the 6
hypertensive cases who had the pro-
thrombin variant and who were HRT
users were also taking the ß-blocker
atenolol, which may have improved their
post-MI survival. In hypertensive
patients, moreover, the presence and the
severity of target organ disease is strongly
associated with several prothrombotic
abnormalities, including elevated lev-
els of D-dimer.43·44 As we have previ-
ously hypothesized,6 die presence of sub-
clinical or clinical cardiovascular disease,
such äs angina or hypertensive disease,
may be important in initiating the pro-
thrombotic effects of estrogens, includ-
ing any potential interaction with the
prothrombin variant. Rosendaal15 has
described the risk of venous thrombo-
sis in terms of multiple interacting
causes, and a similar model may be rel-
evant for arterial thrombotic disease.
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In this case-control study, which ex-
cluded women with a previous MI, the
interaction with the prothrombin vari-
ant was associated with current use of
HRT rather than with recent initiation
of therapy äs in HERS. If a prothrom-
botic third factor such äs coronary ath-
erosclerosis or hypertensive target or-
gan disease is also required,43·44 the onset
of the thrombotic event may be de-
layed until that third factor progresses
far enough or becomes severe enough,
in the presence of the prothrombin vari-
ant and HRT use, to precipitate an MI.
If this third-factor hypothesis is true,
the findings of this study would be ex-
pected to differ from those of HERS in
terms of the time relationship be-
tween MI events and the initiation of
HRT. HERS was a secondary preven-
tion trial that enrolled only women with
clinical coronary disease so that the hy-
pothetical third factor was already pres-
ent from the outset when participants
were randomized and began taking
HRT.
Among hypertensive controls, the
prothrombin variant was present in
only 1.8% of women. An uncommon
susceptibility factor, such äs the pro-
thrombin variant or another associ-
ated with a high risk of events among
HRT users, might account in part for
the pattern of early härm and late ben-
efit seen in the HERS trials.12·13 Simu-
lation studies suggest that the puta-
tive unknown susceptibility factor has
to exhibit both a prevalence of 3% to
5% and a risk ratio of 13 to 25 in HRT
users to reproduce the pattern of early
härm and late benefit seen in HERS.
While the prothrombin variant is a good
candidate, other susceptibility factors
are also likely to be important.
The long-term goal of research in the
area of pharmacogenetics is to help cli-
nicians individualize treatment for their
patients and select drug therapies that
maximize either effectiveness, or safety,
or both. If the HERS findings are in-
deed the result of an interaction be-
tween HRT and a susceptibility factor,
there is an urgent public health need to
identify the putative susceptibility fac-
tor. Based on their biology and preva-
lence, the prothrombin variant and fac-
tor V Leiden were both reasonable
candidates. The findings of this study
suggest the possibility of an interaction
between the prothrombin variant and
HRT use on the incidence of MI among
women with hypertension, but they need
to be confirmed in other settings. If the
findings are confirmed, or if other drug-
gene interactions are identified, clini-
cians may eventually screen postmeno-
pausal women for selected genetic
variants that help characterize a wom-
an's expected risk or benefit from HRT
for a variety of outcomes, including MI,
stroke, and venous thrombosis.
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